Expanding Our Mechanistic Understanding for the Role of the Microbiome in Immuno- Oncology

Time: 11:45 am
day: Day 1 Track A AM


  • Advancing two consortia into the clinic: MB310 in ulcerative colitis and MB097 in advanced melanoma with pembrolizuma
  • Selecting of strains comprising each consortium were due to strong associations with positive outcomes in clinical trials rather than mechanism
  • Exploring translational data which demonstrates the multiple mechanisms by which these bacteria impact host responses linked to disease pathology